'Moon­shot' at liv­er cell ther­a­py biotech Am­bys Med­i­cines comes to an end

Am­bys Med­i­cines, backed by Third Rock Ven­tures and a part­ner to Take­da, closed its doors in re­cent months with­out a big pub­lic dis­clo­sure, but mul­ti­ple em­ploy­ees flashed sig­nals on a net­work­ing site.

The South San Fran­cis­co biotech planned to make a he­pa­to­cyte re­place­ment cell ther­a­py for liv­er dis­ease, but per one for­mer em­ploy­ee, Am­bys “could not con­vince in­vestors to bring this trans­for­ma­tive ther­a­py to pa­tients at this time,” ac­cord­ing to a LinkedIn post. A for­mer ex­ec­u­tive wrote on the job net­work­ing plat­form that the shut­ter­ing was due to “a set of un­for­tu­nate cir­cum­stances.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER